Research Analysts’ Recent Ratings Updates for Astrana Health (ASTH)

Astrana Health (NASDAQ: ASTH) recently received a number of ratings updates from brokerages and research firms:

• 12/29/2025 – Astrana Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Astrana Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Astrana Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/12/2025 – Astrana Health is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $28.00 price target on the stock.
• 12/12/2025 – Astrana Health is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $28.00 price target on the stock.
• 12/8/2025 – Astrana Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Astrana Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Astrana Health had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc..
• 11/25/2025 – Astrana Health had its price target lowered by analysts at Jefferies Financial Group Inc. from $44.00 to $37.00. They now have a “buy” rating on the stock.
• 11/24/2025 – Astrana Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Astrana Health had its price target lowered by analysts at Barclays PLC from $36.00 to $26.00. They now have an “equal weight” rating on the stock.
• 11/17/2025 – Astrana Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – Astrana Health was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating.
• 11/10/2025 – Astrana Health was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 11/10/2025 – Astrana Health had its price target lowered by analysts at TD Cowen from $40.00 to $35.00. They now have a “buy” rating on the stock.
• 11/7/2025 – Astrana Health had its price target lowered by analysts at BTIG Research from $50.00 to $45.00. They now have a “buy” rating on the stock.

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.